abstract：:We studied bioavailability, treatment schedule dependence, and therapeutic efficacy of orally administered MST-16, a novel derivative of bis(2,6-dioxopiperazine), against murine tumors and human tumor xenografts. The rate of its intestinal absorption was about 50%, and it was immediately metabolized to its parent comp...

journal_title：Cancer chemotherapy and pharmacology

authors： Narita T,Koide Y,Yaguchi S,Kimura S,Izumisawa Y,Takase M,Inaba M,Tsukagoshi S

更新日期：1991-01-01 00:00:00

abstract：:The pharmakokinetic profiles of intraperitoneally infused platinum analogues were determined in 13 women exhibiting minimal residual disease following surgery and systemic chemotherapy for epithelial ovarian cancer or fallopian tube carcinoma by following the disposition of tracer doses of 195mPt radiolabel. Six patie...

journal_title：Cancer chemotherapy and pharmacology

authors： Lind MJ,Murphy DJ,Sharma H,Tinker N,Smith A,McAuliffe CA,Crowther D

更新日期：1991-01-01 00:00:00

abstract：:Cyclophosphamide demonstrates enhanced tumoricidal activity with decreased bone marrow toxicity when given on a divided-dose schedule in certain animal models. A total of 22 patients presenting with refractory metastatic cancer were treated in a phase I trial of continuous infusion of cyclophosphamide over 96 h. Granu...

journal_title：Cancer chemotherapy and pharmacology

authors： Eder JP,Elias AD,Ayash L,Wheeler CA,Shea TC,Schnipper LE,Frei E 3rd,Antman KH

更新日期：1991-01-01 00:00:00

abstract：:The aim of the present investigation was to evaluate the potential cardioprotective effect of reduced glutathione (GSH) against the delayed cardiomyopathy induced by doxorubicin (DXR) in a well-documented rat model. DXR was administered i.v. at a weekly dose of 3 mg/kg for a total of 4 doses; 250 or 500 mg/kg of GSH w...

journal_title：Cancer chemotherapy and pharmacology

authors： Villani F,Galimberti M,Zunino F,Monti E,Rozza A,Lanza E,Favalli L,Poggi P

更新日期：1991-01-01 00:00:00

abstract：:Prostaglandins (PGs) have been shown to inhibit tumour metastases in experimental animal systems. Nafazatrom is a pyrazolinone derivative that increases endogenous prostacyclin (PGI2) and has experimental anti-cancer activity. In the present study, nafazatrom was given to 47 women with advanced breast cancer; objectiv...

journal_title：Cancer chemotherapy and pharmacology

authors： Jones AL,Powles TJ,Forgeson GV,Coombes RC

更新日期：1991-01-01 00:00:00

abstract：:A total of 40 patients with metastatic breast cancer were treated with 120 mg/m2 i.v. epirubicin every 3 weeks for a maximum of 10 cycles. Nine achieved a complete response and 17 showed a partial response, for an objective response rate of 65% (95% confidence interval, 47%-83%); the median duration of response was 7 ...

journal_title：Cancer chemotherapy and pharmacology

authors： Carmo-Pereira J,Costa FO,Miles DW,Henriques E,Richards MA,Rubens RD

更新日期：1991-01-01 00:00:00

abstract：:We evaluated the stability of the aqueous formulation of mesna during storage in syringes and after dilution in beverages and syrups. Measurements of the concentrations of mesna showed that the undiluted formulation was stable for at least 9 days in standard polypropylene syringes at 5 degrees, 24 degrees, and 35 degr...

journal_title：Cancer chemotherapy and pharmacology

authors： Goren MP,Lyman BA,Li JT

更新日期：1991-01-01 00:00:00

abstract：:Detailed pharmacokinetic analysis and subsequent evaluation of myelotoxicity were performed in 55 patients who had been randomized to 4 different doses of epirubicin (40, 60, 90 or 135 mg/m2 given i.v. every 3 weeks). A significantly positive correlation was demonstrated between the AUC and the myelotoxicity of epirub...

journal_title：Cancer chemotherapy and pharmacology

authors： Jakobsen P,Bastholt L,Dalmark M,Pfeiffer P,Petersen D,Gjedde SB,Sandberg E,Rose C,Nielsen OS,Mouridsen HT

更新日期：1991-01-01 00:00:00

abstract：:We conducted a double-blind, randomized crossover study to compare the toxicity and antiemetic efficacy of the 5-hydroxytryptamine3 receptor antagonist batanopride with that of metoclopramide in 21 chemotherapy-naive patients receiving at least 70 mg/m2 cisplatin. The study was terminated when hypotension was observed...

journal_title：Cancer chemotherapy and pharmacology

authors： Fleming GF,Vokes EE,McEvilly JM,Janisch L,Francher D,Smaldone L

更新日期：1991-01-01 00:00:00

abstract：:A series of in vitro cytotoxicity studies were performed to achieve pharmacologic reversal of resistance to the alkylating agent mitomycin (MMC) in L-1210 leukemia cells. A multidrug-resistant (MDR), P-glycoprotein-positive cell line, RL-1210/.1 [11], was exposed to potential MDR modulators in the absence or presence ...

journal_title：Cancer chemotherapy and pharmacology

authors： Dorr RT,Liddil JD

更新日期：1991-01-01 00:00:00

abstract：:Doxifluridine (5'-deoxy-5-fluorouridine, 5'-dFUR) metabolism has been reported to be saturable and associated with a fall in clearance of the drug as the dose is increased. The aim of the present study was to determine the disposition of 5'-dFUR and 5-fluorouracil (5-FU) when 5'-dFUR was given as a 5-day infusion, wit...

journal_title：Cancer chemotherapy and pharmacology

authors： Reece PA,Olver IN,Morris RG,Bishop JF,Guentert TW,Hill HS,Hillcoat BL

更新日期：1990-01-01 00:00:00

abstract：:Anaesthetized rabbits were infused with methotrexate (MTX; 30 micrograms x kg-1 x min-1) for 4 h. Constant plasma concentrations of MTX and its main metabolite 7-hydroxymethotrexate (7-OH-MTX) were achieved 40-60 min after the start of the infusion. In all, 50% of the infused MTX was eliminated by the kidney; another ...

journal_title：Cancer chemotherapy and pharmacology

authors： Iven H,Brasch H

更新日期：1990-01-01 00:00:00

abstract：:Pyrazine diazohydroxide (sodium salt, NSC 361456; PZDH) is a new antitumor drug with relatively broad activity in initial evaluations against murine leukemias, solid tumors, and two human tumor xenografts in vivo. The present studies were designed to address questions about PZDH activity on different treatment schedul...

journal_title：Cancer chemotherapy and pharmacology

authors： Harrison SD Jr,Plowman J,Dykes DJ,Waud WR,Griswold DP Jr

更新日期：1990-01-01 00:00:00

abstract：:This phase I study was carried out to determine the maximal tolerated dose of carboplatin (Car) together with a fixed dose of etoposide (E) and to recommend the optimal dose for a phase II study. The dose of E was 100 mg/m2 given i.v. on days 1-3, and the starting dose of Car was 200 mg/m2 given i.v. on day 1. The dos...

journal_title：Cancer chemotherapy and pharmacology

authors： Liippo K,Nikkanen V,Heinonen E

更新日期：1990-01-01 00:00:00

abstract：:Dose fractionation is known to reduce the toxicity of ifosfamide and also results in an increased production of alkylating metabolites. Administration by slow infusion using the convenience of ambulatory pumps is therefore of interest. We used HPLC to investigate the stability of ifosfamide in aqueous solution (either...

journal_title：Cancer chemotherapy and pharmacology

authors： Radford JA,Margison JM,Swindell R,Lind MJ,Wilkinson PM,Thatcher N

更新日期：1990-01-01 00:00:00

abstract：:The radiosensitizing activity, acute toxicity, and pharmacokinetics of a new hypoxic cell radiosensitizer, potassium 2-nitroimidazole-1-acetohydroxamate (KIH-802), were compared with those of misonidazole (MISO) and etanidazole (SR-2508). The radiosensitizing activity of KIH-802 was slightly higher than that of MISO a...

journal_title：Cancer chemotherapy and pharmacology

authors： Sasai K,Shibamoto Y,Takahashi M,Zhou L,Hori H,Nagasawa H,Shibata T,Inayama S,Abe M

更新日期：1990-01-01 00:00:00

abstract：:A total of 22 relapsed or refractory ovarian cancer patients were treated with ifosfamide-containing polychemotherapy. Kinetic analyses were done to evaluate the tumor-cell-recruiting potential of the alkylating agent. Our study shows that ifosfamide can enhance tumor proliferative activity in pretreated ovarian cance...

journal_title：Cancer chemotherapy and pharmacology

authors： Rosso R,Alama A,Repetto L,Conte PF

更新日期：1990-01-01 00:00:00

abstract：:We established an etoposide (VP-16)-resistant human small-cell lung cancer cell line (H69/VP) by stepwise exposure to VP-16. The resistance of H69/VP to VP-16 was 9.4-fold that of the parent cell line (H69/P). H69/VP showed cross-resistance to Adriamycin (ADM), (4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidinopiperidino) c...

journal_title：Cancer chemotherapy and pharmacology

authors： Minato K,Kanzawa F,Nishio K,Nakagawa K,Fujiwara Y,Saijo N

更新日期：1990-01-01 00:00:00

abstract：:The pharmacokinetics of flavone acetic acid (FAA) after a dose of 4.8 mg/m2 given i.v. over 1 h was investigated in 13 patients with different solid tumors. The mean volume of distribution and clearance were 52 +/- 4 l/m2 and 2.6 +/- 0.2 l/h x m2, respectively. A tumor or metastasis biopsy was obtained from six patien...

journal_title：Cancer chemotherapy and pharmacology

authors： Damia G,Freschi A,Sorio R,Braida A,Caruso G,Quaia M,Monfardini S,D'Incalci M

更新日期：1990-01-01 00:00:00

abstract：:Tumor-tissue and plasma concentrations of platinum were studied prospectively in two groups of eight patients who were suffering from advanced non-small-cell lung cancer. Treatments including two different schedules of cisplatin administration (25 vs 100 mg/m2 on day 1) were compared. At 30 min after the beginning of ...

journal_title：Cancer chemotherapy and pharmacology

authors： Pujol JL,Cupissol D,Gestin-Boyer C,Bres J,Serrou B,Michel FB

更新日期：1990-01-01 00:00:00

abstract：:Male Sprague-Dawley rats were given single i.p. injections of 1,3-bis(2-chloroethyl)-1-Nitrosourea (BCNU) to investigate changes in hepatic microsomal cytochrome P-450 content and metabolic activity. On day 14 after treatment (20 mg/kg), cytochrome P-450 content had decreased by approximately 25% and ethylmorphine N-d...

journal_title：Cancer chemotherapy and pharmacology

authors： Stolzenbach JC,Larson RE

更新日期：1990-01-01 00:00:00

abstract：:A phase I trial of indicine-N-oxide was carried out in 12 children with solid tumors and in 16 with leukemia. Doses of 5, 6, and 7.5 g/m2 were given parenterally as a 15-min infusion every 3 weeks. The maximum tolerated dose in patients with solid tumors was 7.5 g/m2 and the dose-limiting toxicity was myelosuppression...

journal_title：Cancer chemotherapy and pharmacology

authors： Whitehead VM,Bernstein ML,Vega R,Vats T,Dyment P,Vietti TJ,Krischer J

更新日期：1990-01-01 00:00:00

abstract：:Unidirectional blood-brain barrier transfer of the lipophilic anticancer agents vincristine and vinblastine was studied in anesthetized rats, using an isolated, in situ brain perfusion technique. Drug binding to plasma constituents was also measured. Despite the high lipophilicity of these agents (the log octanol/phys...

journal_title：Cancer chemotherapy and pharmacology

authors： Greig NH,Soncrant TT,Shetty HU,Momma S,Smith QR,Rapoport SI

更新日期：1990-01-01 00:00:00

abstract：:The therapeutic efficacy of PTT.119, p-F-Phe-m-bis-(2-chloroethyl)amino-L-Phe-Met-ethoxy HCl, was evaluated using the transplantable L1210 leukemia and Ridgway osteogenic sarcoma tumor lines and the spontaneous C3H/StRos mammary tumor and AKR leukemia tumor models. Given in a single i.p. dose at 5-10 mg/kg on day 2 or...

journal_title：Cancer chemotherapy and pharmacology

authors： Yagi MJ,Bekesi JG

更新日期：1990-01-01 00:00:00

abstract：:A highly sensitive enzyme-linked immunosorbent assay (ELISA) for etoposide (EP) was developed, which is capable of accurately measuring as little as 40 pg EP/ml. Anti-EP sera were obtained by immunizing rabbits with EP conjugated with mercaptosuccinyl bovine serum albumin (MS.BSA) using N-[beta-(4-diazophenyl)ethyl]ma...

journal_title：Cancer chemotherapy and pharmacology

authors： Saita T,Fujiwara K,Kitagawa T,Mori M,Takata K

更新日期：1990-01-01 00:00:00

abstract：:Exposure of cells of the K-562 erythroleukemia cell line to 4-hydroperoxycyclophosphamide (4-HC), an analog of activated cyclophosphamide, causes a concentration-dependent inhibition of in vitro colony formation by these cells. For investigation of the role of glutathione (GSH) in the metabolism of 4-HC, GSH levels of...

journal_title：Cancer chemotherapy and pharmacology

authors： Peters RH,Ballard K,Oatis JE,Jollow DJ,Stuart RK

更新日期：1990-01-01 00:00:00

abstract：:Both the capacity of healthy human, cancer patient, and mouse plasma proteins to bind flavone acetic acid (FAA) and the qualitative differences in the plasma protein-binding site were studied. The binding capacity of plasma proteins for FAA was saturated within the therapeutic range in both species. The binding of FAA...

journal_title：Cancer chemotherapy and pharmacology

authors： Brodfuehrer J,Valeriote F,Chan K,Heilbrun L,Corbett T

更新日期：1990-01-01 00:00:00

abstract：:The clinical formulation of leucovorin (5-CHO-FH4) is a mixture of diastereoisomers with markedly different pharmacologic properties. Comparatively little information is available concerning the cellular pharmacology of reduced folate stereoisomers, due largely to the difficulty in preparing sufficient quantities of t...

journal_title：Cancer chemotherapy and pharmacology

authors： Lee PP,Schilsky RL

更新日期：1990-01-01 00:00:00

abstract：:This report describes the physicochemical and pharmacokinetic parameters of seven chlorambucil esters, which were compared with those of chlorambucil. These esters were designed as chlorambucil prodrugs to increase the brain penetration and concentration vs time profile of chlorambucil within the CNS for potential tre...

journal_title：Cancer chemotherapy and pharmacology

authors： Greig NH,Genka S,Daly EM,Sweeney DJ,Rapoport SI

更新日期：1990-01-01 00:00:00

abstract：:The in vitro inhibitory action and metabolism of 1-beta-D-arabinofuranosylcytosine (ara-C) on human myeloid (HL-60), B-lymphoid (RPMI-8392), and T-lymphoid (Molt-3) leukemic cells was compared. Ara-C produced greater inhibitory effects in Molt-3 cells than in either HL-60 or RPMI-8392 cells. At a 48 h exposure, ara-C ...

journal_title：Cancer chemotherapy and pharmacology

authors： Momparler RL,Onetto-Pothier N,Bouffard DY,Momparler LF

更新日期：1990-01-01 00:00:00

abstract：:The toxicity of single doses of the anthracycline epirubicin was compared in the rat after either the intravenous (i.v.; 2-6 mg/kg) or intraperitoneal (i.p.; 4-8 mg/kg) administration of the drug. These doses produced comparable acute toxicity that was characterised by a dose-dependent, transient reduction in body wei...

journal_title：Cancer chemotherapy and pharmacology

authors： Yeung TK,Simmonds RH,Hopewell JW

更新日期：1989-01-01 00:00:00

abstract：:In a phase II study we evaluated the effect and toxicity of a new alkylating agent, PTT-119, in 26 patients with non-Hodgkin's lymphomas (NHL) resistant to or relapsed after other chemotherapy. PTT was scheduled by escalating the dose from 2.0 to 3.3 mg/kg every 3 weeks. Among 21 evaluable patients with NHL, 12 (57%) ...

journal_title：Cancer chemotherapy and pharmacology

authors： Tura S,Mazza P,Gherlinzoni F,Zinzani PL,Poletti G,Visani G,Lemoli RM,Cavo M,Galieni P,Tassi C

更新日期：1989-01-01 00:00:00

abstract：:The stability of solutions of the antitumour antimetabolites, vinca alkaloids, podophyllotoxins, interferons, steroids and platinum drugs as well as maytansine, asparaginase, amsacrine, flavone-8-acetic acid, mitoguazone, and N-phosphonoacetyl-L-aspartate (PALA) is reviewed. Much of the published work has been done wi...

journal_title：Cancer chemotherapy and pharmacology

authors： Bosanquet AG

更新日期：1989-01-01 00:00:00

abstract：:Valinomycin is a depsipeptide antibiotic that selectively translocates potassium ion across biologic membranes. This drug has been reported to display antitumor effects, but its use has been limited by its extreme toxicity. However, its incorporation into lipid vesicles (liposomes) has resulted in a reduction in toxic...

journal_title：Cancer chemotherapy and pharmacology

authors： Daoud SS,Juliano RL

更新日期：1989-01-01 00:00:00

abstract：:A total of 24 patients with advanced colorectal adenocarcinoma were entered into a phase I-II study of 5-fluorouracil (5-FU) and cisplatin, 21 of whom had previously received 5-FU. The starting dose of cisplatin was 20 mg/m2 diluted in 1000 cc normal saline, given over 20 h daily for 5 days, together with 600 mg/m2 5-...

journal_title：Cancer chemotherapy and pharmacology

authors： Petrelli NJ,Madejewicz S,Rustum Y,Herrera L,Creaven PJ,Plager J,Soloman J,Mittelman A

更新日期：1989-01-01 00:00:00

abstract：:Physicochemical properties of two types of adriamycin preparation, suspensions and emulsions prepared for i.a. chemotherapy of hepatocellular carcinoma, were investigated. A suspension was prepared by dispersing adriamycin directly into the lipid contrast medium, Lipiodol, whereas an emulsion was obtained by emulsifyi...

journal_title：Cancer chemotherapy and pharmacology

authors： Katagiri Y,Mabuchi K,Itakura T,Naora K,Iwamoto K,Nozu Y,Hirai S,Ikeda N,Kawai T

更新日期：1989-01-01 00:00:00

abstract：:We reviewed 139 resected patients with hepatocellular carcinoma at our clinic between 1963 and 1987, and using the 118 cases for the period between 1963 and 1986, we analyzed the prognostic factors that influenced the long-term prognosis by comparing the survival curves. Significant differences in the survival pattern...

journal_title：Cancer chemotherapy and pharmacology

authors： Kawano N,Ohmori Y,Inoue S,Nagao T,Morioka Y

更新日期：1989-01-01 00:00:00

abstract：:The cytotoxicity of 5-fluorouracil (5-FU) is due in part to the incorporation of the base into RNA molecules. We assessed the cytotoxicity of 5-FU in human colonic carcinoma HT-29 cells and examined mRNA activity (measured by protein biosynthesis in vivo and in vitro) and the maturation of rRNA precursors as two possi...

journal_title：Cancer chemotherapy and pharmacology

authors： Greenhalgh DA,Parish JH

更新日期：1989-01-01 00:00:00

abstract：:The present study was aimed at answering the question of what patients with hepatocellular carcinomas could obtain long-term benefits from resectional therapy. The 239 patients hepatectomized from 1973 through 1986, with 33 tumor-free, 3-year survivors, were the subjects of the study. The following criteria for long-t...

journal_title：Cancer chemotherapy and pharmacology

authors： Yamanaka N,Okamoto E

更新日期：1989-01-01 00:00:00

abstract：:Using flow cytometry and conventional spectrofluorimetry we have previously shown that chloroethylnitrosoureas (CNUs) can exhibit marked inhibition of cellular enzymes catalysing hydrolysis of fluorescein diacetate (FDA). More potent inhibition was seen for the carbamoylating CNUs, whereas alkylating agents were large...

journal_title：Cancer chemotherapy and pharmacology

authors： Dive C,Workman P,Watson JV

更新日期：1989-01-01 00:00:00